In pancreatic cancer, the Kras mutation occurs in the early stages of tumorigenesis and accounts for approximately 90% of pancreatic ductal adenocarcinomas; it is often combined with other classical mutations (PTEN, etc.)to induce pancreatic cancer, which will be mentioned in the following article (85). Here, KRAS is linked to pancreatic neoplasm.